



Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases

*Corporate Presentation
Sep 2023*

NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)

Safe Harbor Statement



Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Prospective investors should not place undue reliance on forward-looking statements. They speak only as at the date of this Investor Presentation and the Company undertakes no obligation to update these forward-looking statements. Past performance does not guarantee or predict future performance. Moreover, the Company undertakes no obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of the Investor Presentation.

Cantargia – Investment highlights



NOVEL IL1RAP ANTIBODIES, POTENTIAL TO TREAT CANCER & INFLAMMATORY DISEASE

- IL1RAP elevated in most solid and liquid tumors
- IL1RAP signalling drives several autoimmune and inflammatory diseases



NADUNOLIMAB: CLEAR ACTIVITY SIGNALS IN CANCER THERAPY WITH UPCOMING CATALYSTS

- Strong clinical interim results in PDAC and NSCLC, and promising initial results in TNBC; >250 patients treated
- Randomized trial ongoing in TNBC (Phase II top-line data in 2024, futility analysis Q4 2023), Phase IIb trial in preparation for PDAC (top-line data in 2025)



CAN10: OPPORTUNITY IN AUTOIMMUNITY/INFLAMMATION

- Pronounced activity in models of systemic sclerosis, myocarditis, psoriasis, atherosclerosis and inflammation
- Phase I clinical trial ongoing, first results 2024



CORPORATE STRENGTH DRIVING INNOVATION

- Solid cash position with runway to mid/end 2024 (287M SEK cash & equivalents at Q2 2023)
- Robust patent portfolio: IL1RAP antibody target in oncology (2032), nadunolimab (2035) and CAN10 (2041)

Current pipeline

Project	Disease	Type of treatment	Discovery phase	Preclinical phase	Clinical phase I	Clinical phase II	Clinical phase III
Nadunolimab	PDAC	1 st line	Gemcitabine/nab-paclitaxel				
	TNBC	1 st /2 nd line	Carboplatin/gemcitabine				
	NSCLC/ non-squamous NSCLC	1 st /2 nd line	Platinum doublets				
CAN10	Myocarditis, Systemic sclerosis						
CANxx	New opportunities within IL1RAP platform						


PDAC – pancreatic cancer; TNBC – triple-negative breast cancer; NSCLC – non-small cell lung cancer

A microscopic image showing several cells with a textured, granular surface. The image is overlaid with a semi-transparent blue band across the center, which contains the text 'NADUNOLIMAB (CAN04)'. The background is a soft, out-of-focus blue.


NADUNOLIMAB (CAN04)

IL1RAP overexpressed in most solid tumors

IL1RAP EXPRESSION IN SOLID TUMOR TYPES




SEVERAL TUMOR-PROMOTING CELLS EXPRESSING IL1RAP IN THE TUMOR MICROENVIRONMENT




IL1RAP – DISTINCTLY OVEREXPRESSED IN TUMORS; LOW EXPRESSION IN NORMAL TISSUE

Pancreatic cancer – Positive interim data in 1st line patients

Best responses according to iRECIST



OS and iPFS for mITT patients



Nadunolimab combination with Gem/Abraxane in 1st line PDAC (n=73):

- 33% response rate with long PFS and OS
 - Additional 5 (7%) patients had on-treatment benefit beyond progression
- Promising OS (12.9 mo), PFS (7.2 mo) and DCR (71%)
- 2 patients still on treatment

Benchmark efficacy Gem/Abraxane:

ORR 23%; DCR 48%; PFS 5.3 mo; OS 8.5 mo (Von Hoff et al, N Engl J Med 2013)


ORR 36%; DCR 62%; PFS 5.6 mo; OS 9.2 mo (NAPOLI 3 trial, ASCO GI 2023)

PFS AND OS LONGER THAN EXPECTED GIVEN HISTORICAL CONTROL IN PDAC – PHASE IIB TRIAL IN PREPARATION

iCPD – Confirmed Progressive Disease; iUPD – Unconfirmed Progressive Disease; iSD – Stable Disease; iPR – Partial Response (all according to iRECIST)

mITT – Modified Intention to Treat

PDAC – Strong efficacy in patients with high tumor IL1RAP level




Efficacy analysis for IL1RAP High (n=27) vs IL1RAP Low (n=19) PDAC patients:

- Significantly prolonged OS in ILRAP High vs IL1RAP Low patients (14.2 vs 10.6 mo; $p=0.017$)
- Deeper and more durable responses in IL1RAP High subgroup: 11 patients had 50% or more tumor size decrease

NEW DATA SUPPORT ONGOING DEVELOPMENT AND EXPLORATION OF NEW OPPORTUNITIES


PDAC – market opportunity

Expected number of cases US 2023: 64,000



PANCREATIC CANCER IS A MULTI BUSD OPPORTUNITY WITH HIGH MEDICAL NEED

NSCLC – Promising efficacy of nadunolimab combination therapy



High ORR to nadunolimab and platinum doublets in different lines of therapy:

- Gem/Cis 1st/2nd line: ORR 53% (n=30)
- Carbo/Pemtrex 1st/2nd line: ORR 60% (n=5)
- Gem/Cis ≥3rd line: ORR 50% (n=4)

Data presented at ASCO 2023

CONSISTENTLY HIGH RESPONSE RATES WITH NADUNOLIMAB AND PLATINUM DOUBLETS


CR – Complete Response; PR – Partial Response; SD – Stable Disease; PD – Progressive Disease
NCG – Nadunolimab/Cisplatin/Gemcitabine; NCP – Nadunolimab/Carboplatin/Pemetrexed

NSCLC – Long-term benefit with strong signal in non-squamous subtype

	All (n=30)	Historical data ^{1,2}	Non-squamous (n=16)	Non-squamous, historical data ³
Median OS	13.7 mo	10.3 mo	15.9 mo	11.3 mo
Median PFS	7.0 mo	5.1 mo	7.3 mo	4.9 mo
ORR	53%	22-28 %	56%	19%
Complete response	6.7% (n=2)	<1%	12.5% (n=2)	<1%

- Strongest efficacy in non-squamous patients
- Long-term benefit of nadunolimab combination therapy, including two complete responses

Treatment course for each individual patient




Data presented at ASCO 2023

NADUNOLIMAB COMBINATION THERAPY COMPARES VERY FAVORABLY TO HISTORICAL DATA FOR CHEMOTHERAPY ALONE

¹ Schiller et al, N Engl J Med 2002; ² Scagliotti et al, J Clin Oncol 2008; ³ Gandhi et al, N Engl J Med 2018

PD – Progressive Disease; SD – Stable Disease; PR – Partial Response; CR – Complete Response; NCG – Nadunolimab/Cisplatin/Gemcitabine

TNBC – Promising early safety and efficacy



Nadunolimab combination with Gem/Carbo in 1st/2nd line metastatic TNBC:

15 patients enrolled in the dose-escalation phase

- Acceptable safety profile (G-CSF given prophylactically to control neutropenia)
- 12 patients treated long enough for initial efficacy evaluation:
 - **Preliminary ORR: 50%** (1 CR, 5 PR, 4 SD, 2 PD)
- Proceeds to randomized phase including up to 98 additional patients (n=49 per arm)
- Interim futility analysis planned for Q4 2023


RESPONSE RATE OF NADUNOLIMAB COMBINATION THERAPY WELL ABOVE HISTORICAL DATA FOR CHEMOTHERAPY ONLY¹

¹ O'Shaughnessy et al, J Clin Oncol 2014

PD – Progressive Disease; SD – Stable Disease; PR – Partial Response; CR – Complete Response

Key messages

- Most chemotherapies induce chemoresistance already after a few months of therapy. Chemotherapy can upregulate both IL-1 α and IL-1 β , signaling through IL1RAP.
- Clinical results strongly support potential unique first-in-class opportunities in PDAC, NSCLC and TNBC.
- PDAC patients with high IL1RAP respond best to nadunolimab combination therapy despite having a worse prognosis




PROMISING EFFICACY OF NADUNOLIMAB WITH CHEMOTHERAPY – CURRENT FOCUS ON RANDOMIZED CLINICAL TRIALS

A microscopic image showing several cells with a complex, textured surface. The image is overlaid with a semi-transparent blue filter. Two cells are in sharp focus in the upper half, while others are blurred in the background and foreground.

CAN10 – OPPORTUNITY IN AUTOIMMUNE/INFLAMMATORY DISEASE


CAN10 – New clinical asset in autoimmunity/inflammation

- IL1RAP-binding antibody potently blocking IL-1, IL-33 and IL-36, without ADCC
- Unique anti-inflammatory activity observed in different mouse models (myocarditis, systemic sclerosis, psoriasis, inflammation)
- Development focusing on systemic sclerosis and myocarditis, diseases involving multiple IL-1 family cytokines




UNIQUE OPPORTUNITY FOR CAN10 IDENTIFIED IN LIFE-THREATENING DISEASES


CAN10 – Promising effects in several preclinical disease models





Viral myocarditis



Autoimmune myocarditis



Systemic sclerosis



CAN10 SHOWS POTENTIAL IN SEVERAL AUTOIMMUNE/INFLAMMATORY DISEASES WITH HIGH MEDICAL NEED

CAN10 – Project status

Status

- CAN10 safe in GLP tox study
- Strong results in preclinical models of several diseases including lead indications myocarditis and systemic sclerosis
- Phase I ongoing, early planning of patient studies (phase IIa)

Clinical phase I study – First data set during 2024

- Phase I in healthy volunteers (SAD) followed by psoriasis patients (MAD) ongoing in Germany
- Up to 80 individuals (safety, pharmacokinetics, biomarkers)

A microscopic image showing several cells with a textured, mesh-like surface. The cells are primarily in shades of blue and purple. A semi-transparent dark blue horizontal band is positioned across the middle of the image, containing the text 'MILESTONES & INVESTMENT HIGHLIGHTS' in white, uppercase letters.

MILESTONES & INVESTMENT HIGHLIGHTS

Upcoming milestones

Nadunolimab

PDAC	NSCLC	TNBC	CAN10	Additional milestones
<ul style="list-style-type: none">• New translational data Q3 2023• Start Phase IIb trial in 150-200 patients early 2024• Phase IIb top-line data in 2025	<ul style="list-style-type: none">• Efficacy/biomarker data from CANFOUR 2023 and 2024	<ul style="list-style-type: none">• Randomized Phase II (TRIFOUR) – interim futility analysis in Q4 2023• Safety and efficacy data from Phase I in Q4 2023	<ul style="list-style-type: none">• Phase I recruitment and treatment ongoing• Phase I data in 2024	<ul style="list-style-type: none">• New clinical data presented from CIRIFOUR, CAPAFOUR and CESTAFOUR trials• New preclinical and translational results

EXTENSIVE NEWS FLOW EXPECTED DURING 2023 & 24

Cantargia – Investment highlights



NOVEL IL1RAP ANTIBODIES, POTENTIAL TO TREAT CANCER & INFLAMMATORY DISEASE

- IL1RAP elevated in most solid and liquid tumors
- IL1RAP signalling drives several autoimmune and inflammatory diseases



CLEAR ACTIVITY SIGNALS IN CANCER THERAPY; WITH UPCOMING CATALYSTS

- Strong clinical interim results in PDAC and NSCLC, and promising initial results in TNBC; >250 patients treated
- Randomized trial ongoing in TNBC (Phase II top-line data in 2024, futility analysis Q4 2023), Phase IIb trial in preparation for PDAC (top-line data in 2025)



CAN10 OPPORTUNITY IN AUTOIMMUNITY/INFLAMMATION

- Pronounced activity in models of systemic sclerosis, myocarditis, psoriasis, atherosclerosis and inflammation
- Phase I clinical trial ongoing, first results 2024



CORPORATE STRENGTH DRIVING INNOVATION

- Solid cash position with runway to mid/end 2024 (287M SEK cash & equivalents at Q2 2023)
- Robust patent portfolio: IL1RAP antibody target in oncology (2032), nadunolimab (2035) and CAN10 (2041)